Bio-Rad Laboratories, Inc. (BIO.B)
NYSE: BIO.B · Real-Time Price · USD
334.85
0.00 (0.00%)
Nov 1, 2024, 8:30 AM EST - Market closed
Bio-Rad Laboratories Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Revenue | 2,580 | 2,671 | 2,802 | 2,923 | 2,546 | 2,312 | Upgrade
|
| Revenue Growth (YoY) | -5.15% | -4.67% | -4.12% | 14.81% | 10.12% | 0.97% | Upgrade
|
| Cost of Revenue | 1,173 | 1,240 | 1,234 | 1,259 | 1,108 | 1,055 | Upgrade
|
| Gross Profit | 1,407 | 1,431 | 1,568 | 1,663 | 1,438 | 1,257 | Upgrade
|
| Selling, General & Admin | 799.69 | 824.22 | 824.83 | 851.02 | 798.8 | 824.63 | Upgrade
|
| Research & Development | 273.68 | 240.93 | 256.79 | 247.34 | 217.76 | 202.71 | Upgrade
|
| Operating Expenses | 1,073 | 1,065 | 1,082 | 1,098 | 1,017 | 1,027 | Upgrade
|
| Operating Income | 333.89 | 365.7 | 486.82 | 564.74 | 421.33 | 229.66 | Upgrade
|
| Interest Expense | -49.08 | -49.44 | -38.11 | -1.55 | -21.86 | -23.42 | Upgrade
|
| Interest & Investment Income | 82.9 | 100.9 | 58 | 18.9 | 18.2 | 30.5 | Upgrade
|
| Currency Exchange Gain (Loss) | 4.08 | 7.35 | 0.21 | -2.75 | -1.77 | -2.25 | Upgrade
|
| Other Non Operating Income (Expenses) | 2.92 | 4.84 | -5.23 | 0.68 | -1.81 | -0.11 | Upgrade
|
| EBT Excluding Unusual Items | 374.71 | 429.35 | 501.68 | 580.01 | 414.08 | 234.39 | Upgrade
|
| Merger & Restructuring Charges | -27.9 | -27.9 | -4.2 | -64.4 | - | - | Upgrade
|
| Gain (Loss) on Sale of Investments | -1,352 | -1,252 | -5,203 | 4,933 | 4,492 | 2,027 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | - | 1.4 | - | 11.7 | - | Upgrade
|
| Pretax Income | -1,005 | -850.1 | -4,704 | 5,449 | 4,918 | 2,261 | Upgrade
|
| Income Tax Expense | -226.5 | -212.78 | -1,077 | 1,195 | 1,104 | 502.41 | Upgrade
|
| Earnings From Continuing Operations | -778.69 | -637.32 | -3,628 | 4,254 | 3,814 | 1,759 | Upgrade
|
| Net Income | -778.69 | -637.32 | -3,628 | 4,254 | 3,814 | 1,759 | Upgrade
|
| Net Income to Common | -778.69 | -637.32 | -3,628 | 4,254 | 3,814 | 1,759 | Upgrade
|
| Net Income Growth | - | - | - | 11.54% | 116.88% | 381.02% | Upgrade
|
| Shares Outstanding (Basic) | 28 | 29 | 30 | 30 | 30 | 30 | Upgrade
|
| Shares Outstanding (Diluted) | 28 | 29 | 30 | 30 | 30 | 30 | Upgrade
|
| Shares Change (YoY) | -3.47% | -1.93% | -1.40% | 0.16% | -0.08% | -0.15% | Upgrade
|
| EPS (Basic) | -27.41 | -21.82 | -121.79 | 142.61 | 128.13 | 58.93 | Upgrade
|
| EPS (Diluted) | -27.41 | -21.82 | -121.79 | 140.83 | 126.47 | 58.27 | Upgrade
|
| EPS Growth | - | - | - | 11.35% | 117.04% | 381.57% | Upgrade
|
| Free Cash Flow | 247.07 | 218.22 | 81.62 | 535.75 | 476.44 | 359.37 | Upgrade
|
| Free Cash Flow Per Share | 8.70 | 7.47 | 2.74 | 17.74 | 15.80 | 11.91 | Upgrade
|
| Gross Margin | 54.54% | 53.56% | 55.97% | 56.91% | 56.48% | 54.38% | Upgrade
|
| Operating Margin | 12.94% | 13.69% | 17.37% | 19.32% | 16.55% | 9.93% | Upgrade
|
| Profit Margin | -30.18% | -23.86% | -129.45% | 145.57% | 149.83% | 76.08% | Upgrade
|
| Free Cash Flow Margin | 9.58% | 8.17% | 2.91% | 18.33% | 18.72% | 15.55% | Upgrade
|
| EBITDA | 483.49 | 511.6 | 624.12 | 702.34 | 559.93 | 363.86 | Upgrade
|
| EBITDA Margin | 18.74% | 19.15% | 22.27% | 24.03% | 22.00% | 15.74% | Upgrade
|
| D&A For EBITDA | 149.6 | 145.9 | 137.3 | 137.6 | 138.6 | 134.2 | Upgrade
|
| EBIT | 333.89 | 365.7 | 486.82 | 564.74 | 421.33 | 229.66 | Upgrade
|
| EBIT Margin | 12.94% | 13.69% | 17.37% | 19.32% | 16.55% | 9.93% | Upgrade
|
| Effective Tax Rate | - | - | - | 21.93% | 22.44% | 22.22% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.